Crossmark

Counting the cost of public and philanthropic R&D funding: the case of olaparib

Crossref DOI link: https://doi.org/10.1186/s40545-022-00445-9

Published Online: 2022-08-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Schmidt, L. http://orcid.org/0000-0001-6062-7065
Sehic, O.

Wild, C.
License Information

Text and Data Mining valid from 2022-08-16

Version of Record valid from 2022-08-16
More Information

Article History

Received: 6 March 2022

Accepted: 2 August 2022

First Online: 16 August 2022

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare that they have no competing interests.